

Is there an Association Between -2549 Insertion/Deletion Polymorphisms in the Promotor Region of the Gene Encoding for VEGFA as a Risk Factor and the Idiopathic Recurrent Spontaneous Miscarriage in a Sample of Jordanian Women?

Azzam OA^{1*}, Mahgoub SS^{2,3}, Farhan SS⁴, Alrawashdeh HM⁵, Abufraijeh SM⁶ and Abd El kareem HM^{7,8}

¹Department of Obstetrics and Gynecology, Mutah University, Jordan

²Department of Biochemistry and Molecular Biology, Mutah University, Jordan,

³Department of Biochemistry and Molecular Biology, Al-Minia Faculty of Medicine, Egypt

⁴Department of Basic sciences, Al-Rafidain University College, Iraq

⁵Department of Ophthalmology, Ibn-Ahaytham Hospital, Jordan

⁶Department of Obstetrics and Gynecology, College of Medicine, Mutah University, Jordan

⁷Department of Biochemistry and Molecular Biology, Faculty of Medicine, Mutah University, Jordan

⁸Department of Biochemistry and Molecular Biology, Benha Faculty of Medicine, Egypt

Abstract

Background: At least 50% of the cases of recurrent spontaneous miscarriage is aetiologically idiopathic. Recently various genetic polymorphisms have been proposed as susceptibility risk factors for pregnancy loss.

Objective: The aim of the present case control-study is to establish the association between the functional -2549 I/D polymorphisms in the promoter region of the vascular endothelial growth factor A (VEGFA) gene and idiopathic recurrent spontaneous miscarriage (IRSM) in a sample of Jordanian women.

Subjects and Methods: 328 subjects were recruited, 103 and 98 women with primary and secondary IRSM, respectively, 127 normal women were selected as a control group. Genomic DNA was isolated from a blood sample withdrawn from each participant, then, -2549 I/D polymorphisms of the VEGFA gene were genotyped by Polymerase Chain Reaction (PCR).

Results: The obtained results revealed that ID polymorphism and D allele of VEGFA -2549 I/D polymorphisms have the highest frequencies in both primary and secondary IRSM patients, no significant difference between the three groups regarding polymorphisms and allele frequencies, patients with DD+ID genetic models have positive association with high risk of IRSM versus II model, and patients with D allele are more liable to have IRSM than those having I allele, no significant difference in the association of VEGFA -2549 I/D polymorphisms with IRSM in the three genetic models of the primary and secondary IRSM patients.

Conclusion: patients with ID genetic model of -2549 I/D polymorphisms in the VEGFA gene's promoter region and D allele have a higher risk for IRSM.

Keywords: Polymorphisms; Miscarriage; VEGFA; Idiopathic; Insertion/Deletion; Recurrent spontaneous miscarriage are aetiologically idiopathic; PCR

*Correspondence to: Omar A Azzam, Department of Obstetrics and Gynecology, Faculty of Medicine, Mutah University, Jordan, E-mail: oabuazzam@yahoo.com

Citation: Azzam OA, Mahgoub SS, Farhan SS, et al. (2020) Is there an Association Between -2549 Insertion/Deletion Polymorphisms in the Promotor Region of the Gene Encoding for VEGFA as a Risk Factor and the Idiopathic Recurrent Spontaneous Miscarriage in a Sample of Jordanian Women? *Prensa Med Argent (Genetics)*, Volume 106:3. 212.

Received: February 02, 2020; **Accepted:** February 28, 2020; **Published:** March 04, 2020

Introduction

IRSM, the frequent obstetric complication, can be explained as a loss of three or more successive pregnancy prior to the 20th weeks of gestation. Up to 50% of IRSM patients have unknown underlying etiology and it affects 1-5% of the women who are seeking bear children [1]. Different factors like endocrine dysfunctions, autoimmune diseases, and uterine pathologies in addition to environmental and nutritional factors have been demonstrated for their direct and/or indirect effects

on miscarriage [2]. Placental circulation in addition to fetal vasculature should be sufficient for maintaining normal pregnancy which is requiring angiogenesis. Such a process is dependent upon multiple factors, including VEGFA [3].

VEGFA, the potent angiogenic factor, is secreted by both fetal and maternal trophoblastic cells for enhancing vascular permeability, hematopoiesis, endothelial cell proliferation and survival [4]. VEGF has receptors (VEGFR1/Flt-1, VEGFR2/KDR/Flk-1) [5], its functions



are related to human reproduction, including placental organization and fetal angiogenesis, in addition to pre-decidualization and gametogenesis [6]. The rate of expression of VEGFA/VEGFR was the highest in the maternal side of the placenta [7], which is different under conditions of normal pregnancy versus the complicated one. This is because of the abnormalities of angiogenesis during implantation and placenta formation early in pregnancy which may lead to IRSM [3].

The possible role of VEGF has enticed the interest of researchers and clinicians. Thus far, several single nucleotide polymorphisms (SNPs) based on nucleotides substitutions and those dependent on insertion (I) or deletion (D) or both of one or more nucleotides (indels) have been described in the VEGF gene. Several SNPs are identified to be associated with the susceptibility to several cancers, metabolic or vascular disorders [8]. Although several SNPs were discussed in IRSM and other reproductive disorders, the interests in insertion/deletion (I/D) polymorphisms researches become more prominent, due to their participation in genetic and phenotypic divergence and diversity [9,10].

Human VEGF, the highly polymorphic, cell-specific mitogenic gene especially in the promoter, 5'- and 3'- untranslated regions, located on chromosome 6p21.3 has consisted of seven introns and eight exons, spanning approximately 14 kb [11]. More than twenty-five different polymorphisms have been identified in the gene encoding for VEGFA [12] which were suggested to influence the levels of its expression.

The most common genetic association with IRSM that was investigated for 20 polymorphisms are -1154 G/A, +936 C/T, -2578 C/A, and -634 G/C SNPs, the obtained results from these studies are inconsistent [13-15]. In the VEGFA gene, a functional I/D polymorphism is located at position -2549 in the promoter region [16]. The deletion of an 18 base pair (bp) long sequence (D allele) results in a 1.95-fold elevated transcriptional activity compared to the allele containing the insertion (I allele) [17].

VEGF gene -2549 I/D polymorphisms may be related to other diseases. In a recent study, it had been shown that uterine leiomyoma was linked to VEGF gene -2549 I/D polymorphisms [18], while, another study concluded that raised susceptibility to diabetic nephropathy in north Indian population has an association with DD genotype and D allele in I/D polymorphism at -2549 position of VEGF gene [19]. Previous literature had evaluated the effect of VEGF gene polymorphisms on IRSM and revealed novel data [15,20-24]. Our study made a comparison with the previous meta-analysis and to the best of authors, knowledge; it is the first study to be conducted in Jordan.

The aim of our study is to explore whether there is an association between the functional -2549 I/D polymorphism in the promoter region of the VEGFA gene and IRSM in a sample of Jordanian women.

Methodology

Subjects

Two hundred and one women who had experienced at least two successive spontaneous abortions and stillbirths were recruited from out-patient clinics attendants of the Obstetrical Clinic, Obstetrics and Gynecology Department, Al-Karak governmental Hospital. One hundred and twenty-seven women who experienced at least two live births and no abortion and who have no history of infertility were included in the study as a control group. Written informed consent was obtained from each participant in the study. The study was approved by the Medical Ethics, Committee of the Faculty of Medicine, Mutah University.

Exclusion criteria

Women with chromosomal anomalies in either partner, endocrine or metabolic disorders, anti-phospholipid syndrome, autoimmune disease or other systemic diseases, previous arterial or venous thrombosis, or structural uterine anomalies detected by ultrasonography and/or hysteroscopy were excluded from the study.

The subjects enrolled in the study were subdivided into three groups:

- Group I: primary IRSM (n=103) with a history of two or more pregnancy losses but no live birth.
- Group II: secondary IRSM (n=98) experienced three or more pregnancy losses after one live birth.
- Group III: control (n=127) with at least two live births with no abortion nor a history of infertility.

The cases with the history of recurrent pregnancy loss (primary and secondary) were subjected to ultrasound and hysterosalpingography for the detection of anatomic abnormalities of the genital tract such as the woman with a septate uterus were excluded from the study.

-2549 Insertion/Deletion polymorphisms analysis

Five ml of blood was withdrawn from each participant in the study (IRSM patients and the healthy controls) for DNA extraction using the method adopted by Sambrook j, et al. (1989) [25]. The analysis of 18 bp I/D polymorphisms of -2549 in the promoter region of VEGFA gene was determined by PCR in a thermal cycler (Perkin Elmer Cetus, Norwalk, CT, USA) using a pair of primers (sense-5'-CCTGGAGCGTTTTGGTAAA-3' and antisense-5'-ATATAGGAAGCAGCTTGGAA-3') [16]. The reaction total volume was 50 µl containing 100 ng DNA template, 50 mM KCl, 10 mM Tris-HCl, 0.1% Triton X-100, 200 mM each of dATP, dCTP, dGTP and dTTP (Integrated DNA Technologies/USA), 2.5 mM MgCl₂, 0.5 mM of each primer, and 1 U Taq DNA Polymerase (iNtRON Biotechnology/Korea). The reaction started with an initial denaturation for 2 min at 95°C, then, the samples were subjected to 30 cycles of three file program in the thermal cycler (45 sec at 95°C, 30 sec at 55°C) and 1 min at 72°C, followed by a final extension at 72°C for 5 min. The 18 bp I/D polymorphism PCR products were electrophoresed on 2% agarose gel, stained and visualized under UV light. The 100 bp DNA ladder was indicated to the left side of gel, two fragments were revealed two bands 234 bp and 18 bp (not seen) for I allele, and one band 216 bp for D allele.

Statistical analysis

Data were analyzed by IBM SPSS version 20. Pearson's χ^2 and ANOVA tests were used to assess differences between the studied groups. Allele and genotype frequencies were determined by allele counting, Odds ratio (OR) and 95% confidence interval (CI) were also determined. Concordance of the polymorphisms frequencies with Hardy-Weinberg equilibrium was evaluated using χ^2 .

Results

The study of VEGFA -2549 I/D polymorphisms among the different groups (Table 1) revealed that I/D polymorphism is the highest in frequency, while, II gene is the lowest one and there is no statistically significant difference among the three groups ($\chi^2=0.625$, $p=0.960$). The frequency of D allele was the highest in patients with secondary IRSM (61.1%) and the least among the controls (56.3%),



Table 1: Polymorphisms, frequency of the VEGFA -2549 I/D in the IRSM groups (primary and secondary) of women and the controls.

Group/polymorphism	DD (no.%)	ID (no.%)	II (no.%)	χ^2	P value
Control	46 (36.22%)	51 (40.15%)	30 (23.63%)	0.625	0.960
Primary IRSM	36 (34.95%)	44 (42.72%)	23 (23.33%)	-	-
Secondary IRSM	39 (39.80%)	42 (42.86%)	17 (17.34%)	-	-
Total IRSM	75 (37.31%)	86 (42.79%)	40 (19.90%)	-	-

Table 2: Alleles frequency of -2549 I/D polymorphisms in IRSM groups (primary and secondary) and the controls.

Group/allele	D (no.%)	I (no.%)	χ^2	P value
Control	142 (55.90%)	112 (44.10%)	0.341	0.529
Primary IRSM	116 (56.31%)	90 (43.69%)	-	-
Secondary IRSM	120 (61.22%)	76 (38.78%)	-	-
Total IRSM	236 (58.70%)	166 (41.30%)	-	-

while, I allele frequency was higher in the control group (43.7%) than in patients with primary IRSM (43.6%) and secondary IRSM (38.9%) and no statistically significant difference among the three groups ($\chi^2=0.341, p=529$) (Table 2).

The obtained results revealed an OR of 1.28 with 95% CI=0.94 to 1.85) suggesting that the patients with dominant and co-dominant genetic models (DD+ID) had positively associated with the risk of IRSM compared to the recessive genetic model (II). Another comparison between dominant gene (DD) on one side with recessive and co-dominant genes (ID+II) on the other side, showing an OR of 1.24 with 95% CI=0.88 to 1.93 which is still indicating that IRSM is more likely to occur in the patients with the dominant gene. Patients with DD polymorphism had more liability (Odds ratio=1.34 with 95% CI=0.99 to 1.97) to have IRSM than those with the recessive gene (II). In contrast, Patients with DD and II polymorphisms are less likely to have IRSM than patients with ID polymorphism (Odds ratio=0.94 with 95% CI=0.98 to 1.75 and Odds ratio=0.96 with 95% CI=0.83 to 1.44, respectively). The assessment of D and I alleles revealed that patients with D allele are more liable to have IRSM than patients with I allele (Odds ratio=1.33, 95% CI=0.94 to 1.97) (Table 3).

Additionally, the results revealed that there is no statistically significant difference in the association of VEGFA -2549 I/D polymorphisms with IRSM under dominant, recessive and co-dominant genetic models of the primary and secondary IRSM patients, while, the assessment of D and I alleles revealed that IRSM is more likely to occur in patients with D allele more than patients with I allele (Odds ratio=1.33, 95% CI=0.94 to 1.97) (Table 4).

Discussion

IRSM is a disorder affected by factors that are related to genetics and non-genetics. Certain studies have revealed an association between genetic variants as risk factors and IRSM [26-29]. VEGF is the main factor for vasculogenesis in both pathological and physiological conditions [30-32]; it is overexpressed in a variety of tissues, including the reproductive system of women, ischemic tissues, cancers and during cellular transformation [33], the enhancement of angiogenesis up-regulates the plasma level of VEGF [34].

The role of VEGF in both placental and fetal angiogenesis has been concluded from gene studies [35,36]. VEGF is necessary for the oocytes maturation, trophoblasts proliferation, embryo implantation, the placental angiogenesis, and the maternal and fetal blood vessels growth [13,37]. According to the above, it is reasonable that VEGF may be involved in the pathogenesis of IRSM in women.

Table 3: The association of VEGFA -2549 I/D polymorphisms with IRSM in patients versus the controls.

VEGFA polymorphism	OR	95% confidence interval	χ^2
DD+ID versus II	1.28	0.94 to 1.85	0.108
DD versus ID+II	1.24	0.88 to 1.93	0.087
DD versus II	1.34	0.99 to 1.97	0.126
DD versus ID	0.94	0.98 to 1.75	0.212
II versus ID	0.96	0.83 to 1.44	0.263
D versus I	1.31	0.98 to 1.94	0.171

Table 4: The association of VEGFA -2549 I/D polymorphisms with the primary IRSM patients versus the secondary IRSM patients.

VEGFA polymorphism	OR	95% confidence interval	χ^2	P value
DD+ID versus II	0.69	0.72 to 1.47	0.407	0.523
DD versus ID+II	0.81	0.82 to 1.46	0.2	0.655
DD versus II	0.94	0.94 to 1.58	0.014	0.906
DD versus ID	0.87	0.79 to 1.73	0.393	0.531
II versus ID	0.71	0.91 to 1.44	0.299	0.584
D versus I	1.33	0.94 to 1.97	0.131	0.538




Figure 1: IRSM patients with the different VEGFA -2549 I/D polymorphisms. 2% agarose gel electrophoresis for PCR amplicons of VEGFA -2549 I/D polymorphisms, the dominant gene (DD) (234 bp), the recessive gene (II) (216 bp), the co-dominant gene (ID) (216, 234 bp), 100 bp DNA ladder is indicated to the left side of the gel.

Genetic polymorphisms may affect the production of VEGF, like I/D 18 base pair (bp) polymorphism at site -2549 of the VEGF gene which was demonstrated to be involved in the development of many diseases, especially those based on angiogenesis [38], including breast cancer, Alzheimer's disease and preeclampsia [39], [40-42]. The homozygous (DD) and heterozygous deletion (DI) genotypes have more transcriptional activity of the VEGF gene and therefore more production [16].

The obtained results in the present study revealed that the frequency of ID polymorphic form of VEGFA -2549 I/D genetic models among primary, secondary and total IRSM groups of women was higher than II and DD models, while, II polymorphism was the lowest one. The assessment of the frequency of D and I alleles showed that the D allele was the highest in frequency in secondary IRSM women and the least among the controls, I allele frequency was higher in the control group than in women with primary and secondary IRSM. There was no statistically significant difference between the three groups regarding the frequency of polymorphisms and alleles.



VEGFA variants-IRSM interrelationship was confirmed by the following studies, which illustrated the association of labor before 37th weeks of gestation and VEGF 936C/T polymorphisms in Greeks [43] and North Indians study which claimed that subjects with VEGF gene polymorphisms -1154G/A and +936C/T have higher risk of abortion [44], but Lee HH, et al. (2010) who studied Koreans and concluded that VEGF polymorphisms of in IRSM are inconclusive, therefore, further studies are needed to be done with more sample sizes and in different races or ethnicities [45]. Another Brazilian study involving -634, 936 VEGF polymorphisms suggested that no correlations were found in any of the investigated polymorphisms, even among co-dominant, dominant and alleles [46].

Our results suggested that -2549 I/D polymorphisms of the dominant (DD) and co-dominant (ID) models had positively associated with IRSM risk versus the recessive one (II). Also, the comparison between the dominant gene compared to the co-dominant and the recessive ones indicated that IRSM is more likely to occur in the patients with the dominant gene. In contrast, patients with dominant and recessive polymorphisms are less likely to have IRSM than patients with co-dominant polymorphism. Furthermore, it is shown from the results of the present study that patients with D allele are more likely to have IRSM compared to those having I allele, but, no significant difference in the association between the three genetic models and IRSM in primary and secondary patients.

Pereza n, et al (2015) studied -2549 I/D polymorphisms of the VEGFA gene in the promoter region in couples and found that the frequency of ID gene is the highest in both diseased and control patients [24]. This is consistent with the findings of this study, however, the comparison between DD and ID genetic models was less than the results in the present research. Additionally, Hashemi M, et al. (2018) found that the Or of ins/ins versus del/del and del/ins+ins/ins compared to del/del were 2.85 and 2.19, respectively, while, the allelic OR was higher than the values obtained in the present study [21]. However, this inconsistency in the results can be explained by the racial and ethnicity difference of patients.

VEGF -2549 polymorphisms were studied in patients with diabetic retinopathy, where ID genotype was also identified as a potential risk factor for the disease, whereas in other studies, DD polymorphism was detected as a risk factor for diabetic retinopathy, where ID genotype was also identified as a potential risk factor for the disease, whereas in other studies, DD polymorphism was detected as a risk factor for diabetic retinopathy [47,48].

VEGF gene polymorphisms in patients with diabetes mellitus were evaluated; the study identified a statistically significant association between DD and DD+ID genotypes as risk factors, on one hand, D allele on the other hand, and the development of diabetes mellitus and its neuropathic complication, while, the frequency of II genotype was more in the controls suggesting the role of this polymorphism and me allele which was detected to be more frequent than D allele in the controls in the prevention of diabetes mellitus pathogenesis. Those findings are proving the association between the existence of D allele and the increase in the risk of vascular complications of diabetes mellitus [49].

An additional study clarified the role of VEGF SNPs in metabolic syndrome pathogenesis, stating that the association between remains to be evaluated should be done using functional studies by enrolling larger homogenous populations in various racial and ethnic populations [9].

The limitations of this study are including, a relatively small number of IRSM patients. It should be carried out on a larger group of patients to provide the data for explaining the role of -2549 I/D VEGFA gene polymorphisms in the development of IRSM. Also, the correlation between the levels of VEGFA and the different polymorphisms was not included in the present study which is requiring further investigations in the future.

Conclusion

The results of the present study showed that women with ID model of the -2549 I/D polymorphisms in the promoter region of the gene encoding for VEGFA and those who carry D allele are at higher risk to have IRSM. More genetic studies in different ethnic populations for the VEGFA gene polymorphisms regarding larger loci for more SNPs are needed to shed the light on the association between the studied polymorphisms of the VEGFA gene including -2549 I/D genotypes and IRSM in the Jordanian women for the accurate diagnosis and proper management.

References

1. Baek KH, Lee EJ, Kim YS (2007) Recurrent pregnancy loss: the key potential mechanisms. *Trends Mol Med* 13: 310-317.
2. Rai R, Regan L (2006) Recurrent miscarriage. *Lancet* 368: 601-611.
3. Burton GJ, Charnock-Jones DS, Jauniaux E (2009) Regulation of vascular growth and function in the human placenta. *Reproduction* 138: 895-902.
4. Hoeben ANN, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, et al. (2004) Vascular endothelial growth factor and angiogenesis. *Pharmacol Rev* 56: 549-580.
5. Zygumt M, Herr F, Münstedt K, Lang U, Liang OD (2003) Angiogenesis and vasculogenesis in pregnancy. *Eur J Obstet Gynecol Reprod Biol* 110: S10-S18.
6. Andraweera PH, Dekker GA, Roberts CT (2012) The vascular endothelial growth factor family in adverse pregnancy outcomes. *Hum Reprod Update* 18: 436-457.
7. Matjila M, Millar R, Van der Spuy Z, Katz A (2013) The differential expression of Kiss1, MMP9 and angiogenic regulators across the feto-maternal interface of healthy human pregnancies: implications for trophoblast invasion and vessel development. *PLoS One* 8: e63574.
8. Kim YR, Hong S (2015) Association between the polymorphisms of the vascular endothelial growth factor gene and metabolic syndrome. *Biomed reports* 3: 319-326.
9. Chuzhanova NA, Anassis EJ, Ball E V, Krawczak M, Cooper DN (2003) Meta-analysis of indels causing human genetic disease: mechanisms of mutagenesis and the role of local DNA sequence complexity. *Hum Mutat* 21: 28-44.
10. Mills RE, Luttig CT, Larkins CE, Beauchamp A, Tsui C, et al. (2006) An initial map of insertion and deletion (INDEL) variation in the human genome. *Genome Res* 16: 1182-1190.
11. Medford ARL, Godinho SIH, Keen LJ, Bidwell JL, Millar AB (2009) Relationship between vascular endothelial growth factor +936 genotype and plasma/epithelial lining fluid vascular endothelial growth factor protein levels in patients with and at risk for ARDS. *Chest* 136: 457-464.
12. Rogers MS, D'Amato RJ (2006) The effect of genetic diversity on angiogenesis. *Exp Cell Res* 312: 561-574.
13. Su MT, Lin SH, Lee IW, Chen YC, Kuo PL (2011) Association of polymorphisms/haplotypes of the genes encoding vascular endothelial growth factor and its KDR receptor with recurrent pregnancy loss. *Hum Reprod* 26: 758-764.
14. Zhang B, Dai B, Zhang X, Wang Z (2012) Vascular endothelial growth factor and recurrent spontaneous abortion: a meta-analysis. *Gene* 507: 1-8.
15. Xu X, Du C, Li H, Du J, Yan X, et al. (2015) Association of VEGF genetic polymorphisms with recurrent spontaneous abortion risk: a systematic review and meta-analysis. *PLoS One* 10: e0123696.
16. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, et al. (1999) Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. *Hum Immunol* 60: 1245-1249.
17. Yang B, Cross DF, Ollerenshaw M, Millward BA, Demaine AG (2003) Polymorphisms



- of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. *J Diabetes Complications* 17: 1-6.
18. Keshavarzi F, Salimi S, Mohammadpour-gharehbagh A, Teimoori B, Yazdi A, et al. (2017) The- 2549 insertion/deletion polymorphism of VEGF gene associated with uterine leiomyoma susceptibility in women from Southeastern Iran. *Ginekol Pol* 88: 115-119.
 19. Amle D, Mir R, Khaneja A, Agarwal S, Ahlawat R, et al. (2015) Association of 18bp insertion/deletion polymorphism, at- 2549 position of VEGF gene, with diabetic nephropathy in type 2 diabetes mellitus patients of North Indian population. *J Diabetes Metab Disord* 1: 19.
 20. Al-Khateeb GM, Mustafa FE, Sater MS, Almawi WY (2011) Effect of the functional VEGFA- 583C/T variant on vascular endothelial growth factor levels and the risk of recurrent spontaneous miscarriage. *Fertil Steril* 95: 2471-2473.
 21. Hashemi M, Danesh H, Bizhani F, Mokhtari M, Bahari G, et al. (2018) The-2549 insertion/deletion polymorphism in the promoter region of VEGF is associated with the risk of recurrent spontaneous abortion. *Biomed reports* 8: 297-300.
 22. Almawi WY, Saldanha FL, Mahmood NA, Al-Zaman I, Sater MS, et al. (2013) Relationship between VEGFA polymorphisms and serum VEGF protein levels and recurrent spontaneous miscarriage. *Hum Reprod* 28: 2628-2635.
 23. Li L, Donghong L, Shuguang W, Hongbo Z, Jing Z, et al. (2013) Polymorphisms in the vascular endothelial growth factor gene associated with recurrent spontaneous miscarriage. *J Matern Neonatal Med* 26: 686-690.
 24. Perez N, Ostojić S, Smirčić A, Hodžić A, Kapović M, et al. (2015) The- 2549 insertion/deletion polymorphism in the promoter region of the VEGFA gene in couples with idiopathic recurrent spontaneous abortion. *J Assist Reprod Genet* 32: 1789-1794.
 25. Sambrook J, Fritsch EF, Maniatis T (1989) *Molecular cloning: a laboratory manual*. Cold spring harbor laboratory press. Ed. 2.
 26. Barišić A, Perez N, Hodžić A, Ostojić S, Peterlin B (2017) A single nucleotide polymorphism of DNA methyltransferase 3B gene is a risk factor for recurrent spontaneous abortion. *Am J Reprod Immunol* 78: e12765.
 27. Zhang Y, Wu Y, Qiao F, Zeng W (2016) Association between p53 polymorphism at codon 72 and recurrent spontaneous abortion. *J Huazhong Univ Sci Technol* 36: 402-405.
 28. Wang G, Sun J (2017) Interactive effects of Snps located within CD28/B7pathway and environment on susceptibility to recurrent spontaneous abortion. *Cell Physiol Biochem* 43: 2185-2199.
 29. Rah H, Chung KW, Ko KH, Kim ES, Kim JO, et al. (2017) miR-27a and miR-449b polymorphisms associated with a risk of idiopathic recurrent pregnancy loss. *PLoS One* 12: e0177160.
 30. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. *Nat Med* 9: 669-676.
 31. Bautch VL (2012) VEGF-directed blood vessel patterning: from cells to organism. *Cold Spring Harb Perspect Med* 2: a006452.
 32. Byrne AM, Bouchier-Hayes DJ, Harmey JH (2005) Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). *J Cell Mol Med* 9: 777-794.
 33. Iruela-Arispe LM, Dvorak HF (1997) Angiogenesis: a dynamic balance of stimulators and inhibitors. *Thromb Haemost* 78: 672-677.
 34. Gargett CE, Rogers PA (2001) Human endometrial angiogenesis. *Reproduction* 121: 181-186.
 35. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, et al. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. *Nature* 380: 435-439.
 36. De Falco S (2012) The discovery of placenta growth factor and its biological activity. *Exp Mol Med* 44: 1-9.
 37. Jelkmann W (2001) Pitfalls in the measurement of circulating vascular endothelial growth factor. *Clin Chem* 47: 617-623.
 38. He Y, Ni J, Chen S, Jiang Y, Jia S, et al. (2010) The vascular endothelial growth factor-2549 insertion/deletion polymorphism is not associated with susceptibility to hepatocellular carcinoma in Chinese. *DNA Cell Biol* 29: 393-396.
 39. Del Bo R, Scarlato M, Ghezzi S, Martinelli Boneschi F, Fenoglio C, et al. (2005) Vascular endothelial growth factor gene variability is associated with increased risk for AD. *Ann Neurol* 57: 373-380.
 40. Chapuis J, Tian J, Shi J, Benesmain F, Cotel D, et al. (2006) Association study of the vascular endothelial growth factor gene with the risk of developing Alzheimer's disease. *Neurobiol Aging* 27: 1212-1215.
 41. Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, et al. (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. *Clin cancer Res* 11: 3647-3653.
 42. Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, et al. (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. *Breast Cancer Res* 8: R22.
 43. Papazoglou D, Galazios G, Koukourakis MI, Kontomanolis EN, Maltezos E (2004) Association of- 634G/C and 936C/T polymorphisms of the vascular endothelial growth factor with spontaneous preterm delivery. *Acta Obstet Gynecol Scand* 83: 461-465.
 44. Aggarwal S, Parveen F, Faridi RM, Phadke S, Borkar M, et al. (2011) Vascular endothelial growth factor gene polymorphisms in North Indian patients with recurrent miscarriages. *Reprod Biomed Online* 22: 59-64.
 45. Lee HH, Hong SH, Shin SJ, Ko JJ, Oh D, et al. (2010) Association study of vascular endothelial growth factor polymorphisms with the risk of recurrent spontaneous abortion. *Fertil Steril* 93: 1244-1247.
 46. Traina É, Daher S, Moron AF, Sun SY, Franchim CS, et al. (2011) Polymorphisms in VEGF, progesterone receptor and IL-1 receptor genes in women with recurrent spontaneous abortion. *J Reprod Immunol* 88: 53-57.
 47. Buraczynska M, Ksiazek P, Baranowicz-Gaszczyk I, Jozwiak L (20007) Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients. *Nephrol Dial Transplant* 22: 827-832.
 48. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, et al. (2002) A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. *Diabetes* 51: 1635-1639.
 49. Stoian A, Bacărea A, Moțățăianu A, Stoian M, Gliga F, et al. (2014) Vascular endothelial growth factor insertion/deletion gene polymorphism in patients with type 2 diabetes and diabetic peripheral polyneuropathy. *Rom Rev Lab Med* 22: 165-172.